Eliseo Salinas

Dr. Eliseo O. Salinas, MD, is a Chief Research & Development Officer at Passage Bio, Inc. and a President-Research & Development at Phoenixus AG. He is on the Board of Directors at Fortuna Fix Ltd. and ViroChem Pharma, Inc. Dr. Salinas was previously employed as a Chief Scientific Officer & Senior Vice President by ACADIA Pharmaceuticals, Inc., a Chief Medical Officer by New World Laboratories, a President & Chief Scientific Officer by Camp Nine, Inc., a President & Chief Scientific Officer by Relmada Therapeutics, Inc., a President & Chief Scientific Officer by Relmada Therapeutics, Inc. /Old/, an Executive VP, Head-Research & Development by StemCells, Inc., a Chief Medical Officer & Executive Vice President by Elan Corp. Plc, a Chief Medical Officer & Head-Development by Elan Pharmaceuticals, Inc., a Chief Medical Officer, SVP-Research & Development by Adolor Corp., a Chief Scientific Officer by Shire Acquisition, Inc., a Chief Scientific Officer, Executive VP-R&D by Shire Plc /Old/, a VP-Regional Clinical Research & Development by Wyeth Research, a Manager-International Project by Synthélabo SA, a President-Research & Development by Vyera Pharmaceuticals LLC, a Vice President-Clinical Research & Development by Wyeth Corp., and a Vice President-Research by Wyeth-Ayerst Research. He received his doctorate degree from Universidad de Buenos Aires.